NasdaqCM - Delayed Quote USD

PDS Biotechnology Corporation (PDSB)

1.2000
-0.0200
(-1.64%)
At close: May 9 at 4:00:01 PM EDT
1.2700
+0.07
+(5.83%)
After hours: May 9 at 6:44:14 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
36,321.1950
36,321.1950
43,045.2340
41,672.4210
21,439.3110
Operating Income
-36,321.1950
-36,321.1950
-43,045.2340
-41,672.4210
-21,439.3110
Net Non Operating Interest Income Expense
-2,158.3580
-2,158.3580
-1,302.9830
-381.3390
4.3460
Pretax Income
-38,479.5530
-38,479.5530
-44,348.2170
-42,053.7600
-21,434.9650
Tax Provision
-869.1690
-869.1690
-1,406.0190
-1,198.9050
-4,516.4880
Net Income Common Stockholders
-37,610.3840
-37,610.3840
-42,942.1980
-40,854.8550
-16,918.4770
Diluted NI Available to Com Stockholders
-37,610.3840
-37,610.3840
-42,942.1980
-40,854.8550
-16,918.4770
Basic EPS
-1.17
-1.03
-1.39
-1.43
-0.66
Diluted EPS
-1.17
-1.03
-1.39
-1.43
-0.66
Basic Average Shares
34,996.3920
36,452.7070
30,952.0600
28,599.2210
25,597.1250
Diluted Average Shares
34,996.3920
36,452.7070
30,952.0600
28,599.2210
25,597.1250
Total Operating Income as Reported
-36,321.1950
-36,321.1950
-43,045.2340
-41,672.4210
-21,439.3110
Total Expenses
36,321.1950
36,321.1950
43,045.2340
41,672.4210
21,439.3110
Net Income from Continuing & Discontinued Operation
-37,610.3840
-37,610.3840
-42,942.1980
-40,854.8550
-16,918.4770
Normalized Income
-37,610.3840
-37,610.3840
-42,942.1980
-40,854.8550
-16,918.4770
Interest Income
2,514.8160
2,514.8160
2,902.9390
935.1800
4.3460
Interest Expense
4,673.1740
4,673.1740
4,205.9220
1,316.5190
0
Net Interest Income
-2,158.3580
-2,158.3580
-1,302.9830
-381.3390
4.3460
EBIT
-33,806.3790
-33,806.3790
-40,142.2950
-40,737.2410
-21,434.9650
EBITDA
-33,785.2670
-33,785.2670
-40,124.9360
-40,737.1550
-21,429.6080
Reconciled Depreciation
21.1120
21.1120
17.3590
0.0860
5.3570
Net Income from Continuing Operation Net Minority Interest
-37,610.3840
-37,610.3840
-42,942.1980
-40,854.8550
-16,918.4770
Normalized EBITDA
-33,785.2670
-33,785.2670
-40,124.9360
-40,737.1550
-21,429.6080
Tax Rate for Calcs
0
0
0
0
0.0002
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 9/30/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MREO Mereo BioPharma Group plc
2.4100
-0.41%
 
DAWN Day One Biopharmaceuticals, Inc.
6.45
-4.59%
 
XFOR X4 Pharmaceuticals, Inc.
3.3700
+2.43%
 
INZY Inozyme Pharma, Inc.
1.1500
-7.26%
 
AMLX Amylyx Pharmaceuticals, Inc.
4.6100
+0.66%
 
ACRV Acrivon Therapeutics, Inc.
1.1600
-1.69%
 
ZURA Zura Bio Limited
1.2100
-3.97%
 
CLDX Celldex Therapeutics, Inc.
18.33
-6.10%
 
NVCT Nuvectis Pharma, Inc.
8.99
-2.49%
 
SLRX Salarius Pharmaceuticals, Inc.
0.7710
+0.67%